XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue recognition and accounts receivable (Tables)
6 Months Ended
Jun. 30, 2020
Revenue Recognition And Accounts Receivable [Line Items]  
Schedule of Net Sales by Major Product Category by Reporting Segment

The tables below presents net sales by major product category by reporting segment:

 

 

 

Three Months Ended June 30,

 

(U.S. Dollars, in thousands)

 

2020

 

 

2019

 

 

Change

 

Bone Growth Therapies

 

$

28,379

 

 

$

50,109

 

 

 

-43.4

%

Spinal Implants

 

 

18,594

 

 

 

23,226

 

 

 

-19.9

%

Biologics

 

 

11,125

 

 

 

16,744

 

 

 

-33.6

%

Global Spine

 

 

58,098

 

 

 

90,079

 

 

 

-35.5

%

Global Extremities

 

 

15,037

 

 

 

25,771

 

 

 

-41.7

%

Net sales

 

$

73,135

 

 

$

115,850

 

 

 

-36.9

%

 

 

 

Six Months Ended June 30,

 

(U.S. Dollars, in thousands)

 

2020

 

 

2019

 

 

Change

 

Bone Growth Therapies

 

$

73,822

 

 

$

97,392

 

 

 

-24.2

%

Spinal Implants

 

 

41,520

 

 

 

46,129

 

 

 

-10.0

%

Biologics

 

 

25,074

 

 

 

32,476

 

 

 

-22.8

%

Global Spine

 

 

140,416

 

 

 

175,997

 

 

 

-20.2

%

Global Extremities

 

 

37,542

 

 

 

48,965

 

 

 

-23.3

%

Net sales

 

$

177,958

 

 

$

224,962

 

 

 

-20.9

%

Schedule of Components Net Sales

The table below presents product sales and marketing service fees, which are both components of net sales:

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

(U.S. Dollars, in thousands)

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Product sales

 

$

62,435

 

 

$

99,865

 

 

$

153,856

 

 

$

193,799

 

Marketing service fees

 

 

10,700

 

 

 

15,985

 

 

 

24,102

 

 

 

31,163

 

Net sales

 

$

73,135

 

 

$

115,850

 

 

$

177,958

 

 

$

224,962

 

 

Allowances for Expected Credit Losses

The following table provides a detail of changes in the Company’s allowance for expected credit losses for the three and six months ended June 30, 2020:

(U.S. Dollars, in thousands)

 

Three Months Ended June 30, 2020

 

 

Six Months Ended June 30, 2020

 

Allowance for expected credit losses beginning balance

 

$

5,591

 

 

$

3,987

 

Impact of adoption of ASU 2016-13

 

 

 

 

 

1,120

 

Current period provision for expected credit losses

 

 

885

 

 

 

1,564

 

Writeoffs charged against the allowance and other

 

 

(224

)

 

 

(338

)

Effect of changes in foreign exchange rates

 

 

112

 

 

 

31

 

Allowance for expected credit losses ending balance

 

$

6,364

 

 

$

6,364

 

 

ASU 2016-13 [Member]  
Revenue Recognition And Accounts Receivable [Line Items]  
Schedule of Net Impact of Adoption to Balance Sheet The net impact of adoption to the Company’s balance sheet as of January 1, 2020 is presented in the table below. The standard did not have a material impact to the Company’s condensed consolidated statements of operations or cash flows. 

 

(U.S. Dollars, in thousands)

 

December 31, 2019

 

 

Impact

of Adoption

of ASC 326

 

 

January 1, 2020

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents, and restricted cash

 

$

70,403

 

 

$

 

 

$

70,403

 

Accounts receivable, net

 

 

86,805

 

 

 

(1,120

)

 

 

85,685

 

Inventories

 

 

82,397

 

 

 

 

 

 

82,397

 

Prepaid expenses and other current assets

 

 

20,948

 

 

 

 

 

 

20,948

 

Total current assets

 

 

260,553

 

 

 

(1,120

)

 

 

259,433

 

Deferred income taxes

 

 

35,117

 

 

 

233

 

 

 

35,350

 

Other long-term assets

 

 

199,950

 

 

 

 

 

 

199,950

 

Total assets

 

$

495,620

 

 

$

(887

)

 

$

494,733

 

Liabilities and shareholders’ equity

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

$

167,989

 

 

$

 

 

$

167,989

 

Shareholders’ equity

 

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

$

1,902

 

 

$

 

 

$

1,902

 

Additional paid-in capital

 

 

271,019

 

 

 

 

 

 

271,019

 

Retained earnings

 

 

57,749

 

 

 

(887

)

 

 

56,862

 

Accumulated other comprehensive loss

 

 

(3,039

)

 

 

 

 

 

(3,039

)

Total shareholders’ equity

 

 

327,631

 

 

 

(887

)

 

 

326,744

 

Total liabilities and shareholders’ equity

 

$

495,620

 

 

$

(887

)

 

$

494,733